Dr. Neal Shore on Treatment of Elderly Patients With mCRPC

Neal Shore, MD
Published: Wednesday, Sep 14, 2016


Neal Shore, MD, the medical director of Carolina Urologic Research Center, discusses the role for abiraterone in patients with chemotherapy-naive patients with metastatic castration-resistant prostate cancer (mCRPC).
 
The elderly population can be immunocompromised, worsening fatigue, more deconditioning, and they are often already on androgen deprivation therapy (ADT), says Shore.
 
When selecting therapy, it is important not to exasperate issues that may already exist in elderly patients like fatigue, lack of appetite, or their diminished participation in extracurricular type activities, specifically their physician activity. Some elderly patients may also have challenges in cognitive function. Abiraterone is very safe and well-tolerated in that patient population of elderly patients, says Shore.

Neal Shore, MD, the medical director of Carolina Urologic Research Center, discusses the role for abiraterone in patients with chemotherapy-naive patients with metastatic castration-resistant prostate cancer (mCRPC).
 
The elderly population can be immunocompromised, worsening fatigue, more deconditioning, and they are often already on androgen deprivation therapy (ADT), says Shore.
 
When selecting therapy, it is important not to exasperate issues that may already exist in elderly patients like fatigue, lack of appetite, or their diminished participation in extracurricular type activities, specifically their physician activity. Some elderly patients may also have challenges in cognitive function. Abiraterone is very safe and well-tolerated in that patient population of elderly patients, says Shore.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x